Recent technology advances especially transcriptome sequencing and bioinformatics strategy for processing cancer profiling data, make the discovery of more fusion genes in cancers, including a recurrent chimeric transcript DNAJB1-PRKACA in FL-HCC [9] and SLC45A3-ELK4 in prostate cancers [23], etc. These known fusion genes provide key insights into tumor biology and have significant clinical impact by serving as potential diagnostic markers or therapeutic targets. This evidence concerns the gene SLC45A3 and hepatocellular carcinoma.